Physician profile
Vishesh Kumar
NPI 1679838700
$4,444.34
in general payments reported to CMS, 2019-2025
25 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $361 · 2021: $509 · 2022: $947 · 2023: $175 · 2024: $603 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,506.16 | 2019-2025 | Navitor, Mitraclip, Triclip |
| Novartis Pharmaceuticals Corporation | $430.03 | 2019-2025 | |
| Astellas Pharma US INC | $421.10 | 2019-2022 | |
| Boston Scientific Corporation | $356.74 | 2022-2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.93 | 2019-2023 | Lifevest |
| Pfizer INC. | $219.56 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $202.94 | 2024-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $161.82 | 2025 | Optimizer |
| Amgen INC. | $152.08 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.09 | 2020-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $91.24 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $82.64 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $74.61 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $58.56 | 2019-2021 | |
| Lundbeck LLC | $52.87 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $42.05 | 2024-2025 | Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $35.89 | 2020-2021 | |
| Chiesi USA, INC. | $28.32 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $24.65 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $19.45 | 2022 | |
| Philips North America LLC | $19.14 | 2020 | |
| United Therapeutics Corporation | $16.40 | 2019 | |
| Merck Sharp & Dohme LLC | $15.36 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $15.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.69 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.